{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-007640","form_type":"8-K","ticker":"BVS","cik":"0001665988","company_name":"Bioventus Inc.","filed_at":"2024-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.036215+00:00","generated_at":"2026-06-06T23:56:48.000242+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Bioventus accelerates vesting of former Interim CEO Bihl's equity awards upon CEO transition","bullets":["Board accelerated all outstanding and unvested equity awards of Anthony P. Bihl III effective January 9, 2024.","Equity awards were originally set to vest in April 2024; acceleration was discretionary under award terms.","Bihl served as Interim President and CEO since April 2023; Robert E. Claypoole succeeded him on January 10, 2024.","Acceleration based on Bihl's performance and contributions to the Company."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-007640","json":"https://secwatch.observer/filing/0001193125-24-007640.json","markdown":"https://secwatch.observer/filing/0001193125-24-007640.md","text":"https://secwatch.observer/filing/0001193125-24-007640.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1665988/000119312524007640/0001193125-24-007640-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1665988/000119312524007640/d727616d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T23:56:48.000242+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"21067a7b1f","claim":"Robert E. Claypoole was appointed as President and Chief Executive Officer at Bioventus Inc..","evidence_excerpt":"As previously reported, Robert E. Claypoole succeeded Mr. Bihl as President and Chief Executive Officer of the Company on January 10, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1665988/000119312524007640/0001193125-24-007640-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"succeeded"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"916af15f3f","claim":"Anthony P. Bihl III departed as Interim President and Chief Executive Officer at Bioventus Inc..","evidence_excerpt":"As previously reported, Robert E. Claypoole succeeded Mr. Bihl as President and Chief Executive Officer of the Company on January 10, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1665988/000119312524007640/0001193125-24-007640-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Role","value":"Interim President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}